Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center

Krina K. Patel, MD, MSc, discusses the effect of high-risk features on outcomes with ide-cel in triple-class–exposed, relapsed/refractory multiple myeloma.

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

The panel debates the options for treatment of late relapsed multiple myeloma.

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

The panel closes their discussion by highlighting unmet needs in the multiple myeloma treatment landscape and sharing advice for physicians and patients.

Krina Patel, MD, explains the treatment options for patients with early relapsed multiple myeloma.

Jenny Ahlstrom, a patient with multiple myeloma, shares considerations for patients going through treatment, including toxicities, follow-up, and travel planning.

Shaji Kumar, MD, and Krina Patel, MD, discuss the treatment options for patients with newly-diagnosed multiple myeloma who are not eligible for stem cell transplant.

Dr Krina Patel discusses updates in the treatment of newly-diagnosed from recent meetings how the appropriate treatments are selected in patients with newly-diagnosed multiple myeloma.

Dr Shaji Kumar reviews clinical trial data on the role of stem cell transplant as a treatment for newly-diagnosed multiple myeloma in tandem with a multi-agent combination therapy.

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Krina Patel, MD, details the three- and four-drug regimen first-line treatment options for transplant-eligible newly-diagnosed multiple myeloma and how to make an appropriate treatment decision.

Shaji Kumar, MD, provides an overview of multiple myeloma, and Jenny Ahlstrom, a patient with multiple myeloma, shares the story of her diagnosis and the resources she used to educate herself.

Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.

Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.